Do analysts prefer AKTX or LABT?

Akari Therapeutics currently has a consensus price target of $32.33, indicating a potential upside of 283.55%. Given Akari Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Akari Therapeutics is more favorable than Lakewood-Amedex Biotherapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Akari Therapeutics 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 Lakewood-Amedex Biotherapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation & earnings, AKTX or LABT?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Akari Therapeutics N/A N/A -$17.30M N/A N/A Lakewood-Amedex Biotherapeutics N/A N/A N/A -$2.00 N/A

Is AKTX or LABT more profitable?

Lakewood-Amedex Biotherapeutics' return on equity of 0.00% beat Akari Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Akari Therapeutics N/A -123.29% -63.01% Lakewood-Amedex Biotherapeutics N/A N/A N/A

Do analysts rate COCP or LABT?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cocrystal Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Lakewood-Amedex Biotherapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings & valuation, COCP or LABT?

Cocrystal Pharma is trading at a lower price-to-earnings ratio than Lakewood-Amedex Biotherapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cocrystal Pharma N/A N/A -$8.83M -$0.73 N/A Lakewood-Amedex Biotherapeutics N/A N/A N/A -$2.00 N/A

Is COCP or LABT more profitable?

Lakewood-Amedex Biotherapeutics' return on equity of 0.00% beat Cocrystal Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Cocrystal Pharma N/A -150.61% -97.86% Lakewood-Amedex Biotherapeutics N/A N/A N/A

Does the media favor COCP or LABT?

In the previous week, Lakewood-Amedex Biotherapeutics had 1 more articles in the media than Cocrystal Pharma. MarketBeat recorded 3 mentions for Lakewood-Amedex Biotherapeutics and 2 mentions for Cocrystal Pharma. Cocrystal Pharma's average media sentiment score of 0.93 beat Lakewood-Amedex Biotherapeutics' score of 0.63 indicating that Cocrystal Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cocrystal Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lakewood-Amedex Biotherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend LNAI or LABT?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lunai Bioworks 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Lakewood-Amedex Biotherapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation & earnings, LNAI or LABT?

Lunai Bioworks is trading at a lower price-to-earnings ratio than Lakewood-Amedex Biotherapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lunai Bioworks N/A N/A -$178.01M -$0.40 N/A Lakewood-Amedex Biotherapeutics N/A N/A N/A -$2.00 N/A

Is LNAI or LABT more profitable?

Lakewood-Amedex Biotherapeutics' return on equity of 0.00% beat Lunai Bioworks' return on equity. Company Net Margins Return on Equity Return on Assets Lunai Bioworks N/A -1,243.45% -1,617.76% Lakewood-Amedex Biotherapeutics N/A N/A N/A

Do analysts recommend LABT or BLRX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lakewood-Amedex Biotherapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 BioLineRx 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer LABT or BIVI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lakewood-Amedex Biotherapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 BioVie 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation and earnings, LABT or BIVI?

Lakewood-Amedex Biotherapeutics is trading at a lower price-to-earnings ratio than BioVie, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lakewood-Amedex Biotherapeutics N/A N/A N/A -$2.00 N/A BioVie N/A N/A -$17.54M -$2.45 N/A

Is LABT or BIVI more profitable?

Lakewood-Amedex Biotherapeutics' return on equity of 0.00% beat BioVie's return on equity. Company Net Margins Return on Equity Return on Assets Lakewood-Amedex Biotherapeutics N/A N/A N/A BioVie N/A -101.15% -90.18%

Does the media refer more to LABT or BIVI?

In the previous week, Lakewood-Amedex Biotherapeutics had 1 more articles in the media than BioVie. MarketBeat recorded 3 mentions for Lakewood-Amedex Biotherapeutics and 2 mentions for BioVie. BioVie's average media sentiment score of 0.93 beat Lakewood-Amedex Biotherapeutics' score of 0.63 indicating that BioVie is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lakewood-Amedex Biotherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioVie 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Lakewood-Amedex Biotherapeutics (LABT) Competitors

$2.10 -0.40 (-16.00%)

Closing price 04:00 PM Eastern

Extended Trading

$2.07 -0.03 (-1.43%)

As of 04:58 PM Eastern

Compare

LABT vs. AKTX, COCP, LNAI, BLRX, and BIVI

Should you buy Lakewood-Amedex Biotherapeutics stock or one of its competitors? MarketBeat compares Lakewood-Amedex Biotherapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Lakewood-Amedex Biotherapeutics include Akari Therapeutics (AKTX), Cocrystal Pharma (COCP), Lunai Bioworks (LNAI), BioLineRx (BLRX), and BioVie (BIVI). These companies are all part of the "pharmaceutical products" industry.

How does Lakewood-Amedex Biotherapeutics compare to Akari Therapeutics?

Akari Therapeutics (NASDAQ:AKTX) and Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, earnings, profitability, risk, analyst recommendations, valuation, institutional ownership and dividends.

Lakewood-Amedex Biotherapeutics' return on equity of 0.00% beat Akari Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Akari Therapeutics	N/A	-123.29%	-63.01%
Lakewood-Amedex Biotherapeutics	N/A	N/A	N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Akari Therapeutics	N/A	N/A	-$17.30M	N/A	N/A
Lakewood-Amedex Biotherapeutics	N/A	N/A	N/A	-$2.00	N/A

5.1% of Akari Therapeutics shares are held by institutional investors. 32.2% of Akari Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Akari Therapeutics had 1 more articles in the media than Lakewood-Amedex Biotherapeutics. MarketBeat recorded 4 mentions for Akari Therapeutics and 3 mentions for Lakewood-Amedex Biotherapeutics. Lakewood-Amedex Biotherapeutics' average media sentiment score of 0.63 beat Akari Therapeutics' score of 0.59 indicating that Lakewood-Amedex Biotherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Akari Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lakewood-Amedex Biotherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Akari Therapeutics currently has a consensus price target of $32.33, indicating a potential upside of 283.55%. Given Akari Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Akari Therapeutics is more favorable than Lakewood-Amedex Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Akari Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Lakewood-Amedex Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Akari Therapeutics beats Lakewood-Amedex Biotherapeutics on 6 of the 9 factors compared between the two stocks.

How does Lakewood-Amedex Biotherapeutics compare to Cocrystal Pharma?

Cocrystal Pharma (NASDAQ:COCP) and Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) are both small-cap pharmaceutical products companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, earnings, risk, valuation, institutional ownership, media sentiment, dividends and analyst recommendations.

6.7% of Cocrystal Pharma shares are owned by institutional investors. 39.4% of Cocrystal Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cocrystal Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Lakewood-Amedex Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Lakewood-Amedex Biotherapeutics had 1 more articles in the media than Cocrystal Pharma. MarketBeat recorded 3 mentions for Lakewood-Amedex Biotherapeutics and 2 mentions for Cocrystal Pharma. Cocrystal Pharma's average media sentiment score of 0.93 beat Lakewood-Amedex Biotherapeutics' score of 0.63 indicating that Cocrystal Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cocrystal Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lakewood-Amedex Biotherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cocrystal Pharma is trading at a lower price-to-earnings ratio than Lakewood-Amedex Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cocrystal Pharma	N/A	N/A	-$8.83M	-$0.73	N/A
Lakewood-Amedex Biotherapeutics	N/A	N/A	N/A	-$2.00	N/A

Lakewood-Amedex Biotherapeutics' return on equity of 0.00% beat Cocrystal Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cocrystal Pharma	N/A	-150.61%	-97.86%
Lakewood-Amedex Biotherapeutics	N/A	N/A	N/A

Summary

Cocrystal Pharma and Lakewood-Amedex Biotherapeutics tied by winning 4 of the 8 factors compared between the two stocks.

How does Lakewood-Amedex Biotherapeutics compare to Lunai Bioworks?

Lunai Bioworks (NASDAQ:LNAI) and Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) are both small-cap manufacturing companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, risk, earnings, institutional ownership, analyst recommendations and valuation.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lunai Bioworks	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Lakewood-Amedex Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Lakewood-Amedex Biotherapeutics had 2 more articles in the media than Lunai Bioworks. MarketBeat recorded 3 mentions for Lakewood-Amedex Biotherapeutics and 1 mentions for Lunai Bioworks. Lunai Bioworks' average media sentiment score of 1.89 beat Lakewood-Amedex Biotherapeutics' score of 0.63 indicating that Lunai Bioworks is being referred to more favorably in the media.

Company	Overall Sentiment
Lunai Bioworks	Very Positive
Lakewood-Amedex Biotherapeutics	Positive

71.4% of Lunai Bioworks shares are owned by institutional investors. 0.5% of Lunai Bioworks shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Lunai Bioworks is trading at a lower price-to-earnings ratio than Lakewood-Amedex Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lunai Bioworks	N/A	N/A	-$178.01M	-$0.40	N/A
Lakewood-Amedex Biotherapeutics	N/A	N/A	N/A	-$2.00	N/A

Lakewood-Amedex Biotherapeutics' return on equity of 0.00% beat Lunai Bioworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lunai Bioworks	N/A	-1,243.45%	-1,617.76%
Lakewood-Amedex Biotherapeutics	N/A	N/A	N/A

Summary

Lunai Bioworks and Lakewood-Amedex Biotherapeutics tied by winning 4 of the 8 factors compared between the two stocks.

How does Lakewood-Amedex Biotherapeutics compare to BioLineRx?

Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) and BioLineRx (NASDAQ:BLRX) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, earnings, dividends, risk, valuation and media sentiment.

In the previous week, Lakewood-Amedex Biotherapeutics had 2 more articles in the media than BioLineRx. MarketBeat recorded 3 mentions for Lakewood-Amedex Biotherapeutics and 1 mentions for BioLineRx. BioLineRx's average media sentiment score of 1.89 beat Lakewood-Amedex Biotherapeutics' score of 0.63 indicating that BioLineRx is being referred to more favorably in the news media.

Company	Overall Sentiment
Lakewood-Amedex Biotherapeutics	Positive
BioLineRx	Very Positive

1.6% of BioLineRx shares are owned by institutional investors. 1.1% of BioLineRx shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Lakewood-Amedex Biotherapeutics has a net margin of 0.00% compared to BioLineRx's net margin of -563.70%. Lakewood-Amedex Biotherapeutics' return on equity of 0.00% beat BioLineRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lakewood-Amedex Biotherapeutics	N/A	N/A	N/A
BioLineRx	-563.70%	-37.73%	-19.42%

Lakewood-Amedex Biotherapeutics has higher earnings, but lower revenue than BioLineRx. BioLineRx is trading at a lower price-to-earnings ratio than Lakewood-Amedex Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lakewood-Amedex Biotherapeutics	N/A	N/A	N/A	-$2.00	N/A
BioLineRx	$1.18M	10.44	-$1.17M	-$1.92	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lakewood-Amedex Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
BioLineRx	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Lakewood-Amedex Biotherapeutics and BioLineRx tied by winning 5 of the 10 factors compared between the two stocks.

How does Lakewood-Amedex Biotherapeutics compare to BioVie?

Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) and BioVie (NASDAQ:BIVI) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, analyst recommendations, valuation, profitability, earnings, dividends and risk.

Lakewood-Amedex Biotherapeutics' return on equity of 0.00% beat BioVie's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lakewood-Amedex Biotherapeutics	N/A	N/A	N/A
BioVie	N/A	-101.15%	-90.18%

In the previous week, Lakewood-Amedex Biotherapeutics had 1 more articles in the media than BioVie. MarketBeat recorded 3 mentions for Lakewood-Amedex Biotherapeutics and 2 mentions for BioVie. BioVie's average media sentiment score of 0.93 beat Lakewood-Amedex Biotherapeutics' score of 0.63 indicating that BioVie is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lakewood-Amedex Biotherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioVie	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lakewood-Amedex Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
BioVie	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Lakewood-Amedex Biotherapeutics is trading at a lower price-to-earnings ratio than BioVie, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lakewood-Amedex Biotherapeutics	N/A	N/A	N/A	-$2.00	N/A
BioVie	N/A	N/A	-$17.54M	-$2.45	N/A

4.6% of BioVie shares are owned by institutional investors. 0.9% of BioVie shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Lakewood-Amedex Biotherapeutics and BioVie tied by winning 4 of the 8 factors compared between the two stocks.

Get Lakewood-Amedex Biotherapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LABT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LABT vs. The Competition

Export

Metric	Lakewood-Amedex Biotherapeutics	Pharmaceutical Preparations Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$3.68M	$946.10M	$6.85B	$12.19B
Dividend Yield	N/A	4.84%	31.69%	8.55%
P/E Ratio	-1.05	1.52	23.61	23.75
Price / Sales	N/A	109.14	130.67	88.01
Price / Cash	N/A	20.06	165.24	59.05
Price / Book	N/A	8.45	12.86	6.06
Net Income	N/A	-$3.57M	$120.03M	$336.44M
7 Day Performance	12.90%	-0.36%	-2.39%	-2.14%
1 Month Performance	-40.17%	-6.22%	-4.31%	-3.32%
1 Year Performance	N/A	26.14%	10.07%	13.49%

Lakewood-Amedex Biotherapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LABT Lakewood-Amedex Biotherapeutics	0.9406 of 5 stars	$2.10 -16.0%	N/A	N/A	$3.68M	N/A	N/A	5	Gap Down
AKTX Akari Therapeutics	3.4825 of 5 stars	$11.01 -4.3%	$33.50 +204.3%	-80.9%	$13.16M	N/A	N/A	9	Analyst Downgrade Gap Down
COCP Cocrystal Pharma	0.4478 of 5 stars	$0.95 0.0%	N/A	-42.6%	$13.10M	N/A	N/A	10
LNAI Lunai Bioworks	0.9035 of 5 stars	$2.82 -2.1%	N/A	N/A	$13.06M	N/A	N/A	20	Positive News
BLRX BioLineRx	0.525 of 5 stars	$2.90 -2.7%	N/A	-33.6%	$13.02M	$1.18M	N/A	40	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LABT) was last updated on 7/28/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lakewood-Amedex Biotherapeutics (LABT) Competitors

LABT vs. AKTX, COCP, LNAI, BLRX, and BIVI

How does Lakewood-Amedex Biotherapeutics compare to Akari Therapeutics?

Summary

How does Lakewood-Amedex Biotherapeutics compare to Cocrystal Pharma?

Summary

How does Lakewood-Amedex Biotherapeutics compare to Lunai Bioworks?

Summary

How does Lakewood-Amedex Biotherapeutics compare to BioLineRx?

Summary

How does Lakewood-Amedex Biotherapeutics compare to BioVie?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LABT vs. The Competition

Lakewood-Amedex Biotherapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Lakewood-Amedex Biotherapeutics (LABT) Competitors

LABT vs. AKTX, COCP, LNAI, BLRX, and BIVI

How does Lakewood-Amedex Biotherapeutics compare to Akari Therapeutics?

Is AKTX or LABT more profitable?

Which has stronger valuation & earnings, AKTX or LABT?

Do institutionals & insiders believe in AKTX or LABT?

Does the media refer more to AKTX or LABT?

Do analysts prefer AKTX or LABT?

Summary

How does Lakewood-Amedex Biotherapeutics compare to Cocrystal Pharma?

Do insiders & institutionals have more ownership in COCP or LABT?

Do analysts rate COCP or LABT?

Does the media favor COCP or LABT?

Which has preferable earnings & valuation, COCP or LABT?

Is COCP or LABT more profitable?

Summary

How does Lakewood-Amedex Biotherapeutics compare to Lunai Bioworks?

Do analysts recommend LNAI or LABT?

Does the media prefer LNAI or LABT?

Do institutionals and insiders have more ownership in LNAI or LABT?

Which has stronger valuation & earnings, LNAI or LABT?

Is LNAI or LABT more profitable?

Summary

How does Lakewood-Amedex Biotherapeutics compare to BioLineRx?

Does the media prefer LABT or BLRX?

Do insiders & institutionals hold more shares of LABT or BLRX?

Is LABT or BLRX more profitable?

Which has stronger earnings & valuation, LABT or BLRX?

Do analysts recommend LABT or BLRX?

Summary

How does Lakewood-Amedex Biotherapeutics compare to BioVie?

Is LABT or BIVI more profitable?

Does the media refer more to LABT or BIVI?

Do analysts prefer LABT or BIVI?

Which has preferable valuation and earnings, LABT or BIVI?

Do institutionals & insiders believe in LABT or BIVI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LABT vs. The Competition

Lakewood-Amedex Biotherapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools